Organization (Other)
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
ClinicalTrials.gov lists Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. as lead sponsor of 48 trials. It has 24 active development programs and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.: 48 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (5)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Tuberculosis | 17 |
| COVID-19 | 12 |
| Latent Tuberculosis | 4 |
| Influenza, Human | 1 |
| Urinary Bladder Neoplasms | 1 |
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 3 |
| 2024 | 1 |
| 2023 | 9 |
| 2022 | 6 |
| 2021 | 11 |
| 2020 | 8 |
| 2019 | 1 |
| 2018 | 1 |
| 2016 | 2 |
| 2015 | 2 |
Showing 10 of 12 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 7 months across 37 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (24)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| BCG for Therapeutic Use | Urinary Bladder Neoplasms | Phase 3 | 1 |
| Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) | COVID-19 | Phase 3 | 4 |
| Recombinant new coronavirus vaccine (CHO cell) group | COVID-19 | Phase 3 | 3 |
| Recombinant Mycobacterium Tuberculosis Fusion Protein | Tuberculosis | Phase 3 | 1 |
| Recombinant Mycobacterium Tuberculosis Fusion Protein | Latent Tuberculosis | Phase 3 | 1 |
Showing 5 of 24 active programs.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Recombinant new coronavirus vaccine (CHO cell) | 2 |
| TB-PPD was injected | 1 |
| Recombinant Mycobacterium tuberculosis fusion protein for injection | 1 |
| Mycobacterium Vaccae for Injection | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 78% hit target (n=18) | 45% on time (n=22) |
Journals published in (32)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Infection and immunity | 5 |
| Vaccine | 5 |
| Clinical and diagnostic laboratory immunology | 3 |
| Journal of immunology (Baltimore, Md. : 1950) | 3 |
| The Journal of infectious diseases | 3 |
Showing 5 of 32 journals.
Organization relationships (9)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Beijing Kangterike Statistical Technology Co., Ltd. | Co sponsors trial with | 2 |
| Wuhan Institute for Tuberculosis Control | Co sponsors trial with | 2 |
| Liuzhou Center for Disease Control and Prevention,China | Co sponsors trial with | 1 |
| Jurong Province Centers for Disease Control and Prevention | Co sponsors trial with | 1 |
| Jurong Centers for Disease Control and Prevention | Co sponsors trial with | 1 |
Showing 5 of 9 relationships.
Latest dated events (48)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-05-26 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-05-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-04-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-07-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-11-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 48 events.
Biomarker capability evidence (8)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| F3 | Trial sponsor | Named in trial inclusion criteria |
| F3 | Trial sponsor | Named in trial inclusion criteria |
| IL3 | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial exclusion criteria |
| ALB | Trial sponsor | Mentioned in trial text |
Showing 5 of 8 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.